Sex drive on the dose climb, and after it

The question underneath the question

"Will my sex drive come back once I stop going up?"

It is one of the most reasonable things to wonder, because it contains a real observation: a lot of women notice that the weeks after a dose increase are the weeks when they feel least like themselves. Nauseated, tired, faintly unwell, and not remotely interested.

The answer splits into two halves, and almost everything written about this blurs them together. One half is well documented. The other has not been studied at all. Keeping them apart is the whole point of this page.

Some links below are to programs we may earn a referral fee from; it never changes our ranking. See our disclosure.

The half that is documented

Side effects really do cluster during the climb.

SURMOUNT-5 was a phase 3 trial published in the New England Journal of Medicine in 2025, comparing tirzepatide against semaglutide in 751 adults with obesity and without diabetes, over 72 weeks¹. It is a serious, large, head-to-head comparison — for context, it found average weight reduction of 20.2% on tirzepatide and 13.7% on semaglutide at 72 weeks¹.

The finding that matters here is about tolerability. The most common adverse events in both groups were gastrointestinal, and most were mild to moderate in severity and occurred primarily during dose escalation¹.

That is the sentence worth holding onto. The worst of how you feel is concentrated in the climbing phase, and it is not a permanent setting. If you feel roughest in the two or three weeks after a step up, you are experiencing the documented pattern rather than a personal failure to tolerate the drug.

The half nobody has studied

Now the honest part.

SURMOUNT-5 did not measure sexual function. Not desire, not arousal, not satisfaction, not frequency. No sexual endpoint appears in it at all¹.

So the chain that feels obvious — side effects peak during escalation, side effects suppress desire, therefore desire recovers at maintenance — has a documented first link and an untested second one. Nobody has run the study that follows women's sexual function across the escalation and maintenance phases of a GLP-1.

That means anyone telling you confidently that your libido will return once you reach your maintenance dose is telling you something that has not been demonstrated. It is a plausible expectation. It is not a finding, and you deserve to know which one you are being handed.

Why the inference is still worth something

Not knowing is not the same as knowing nothing.

What is established is that the physical burden — the nausea, the fullness, the general sense of being unwell — is heaviest during escalation and lighter afterwards¹. It is entirely reasonable to expect that feeling physically better makes room for wanting sex, because feeling ill is not a state most people feel desire in.

What that reasoning cannot tell you is how much, or how fast, or whether it happens for you at all. Desire on these medications does not move in one direction for everyone — some women report more, some report much less, and the research genuinely points both ways. That is the subject of libido and desire on a GLP-1, which is the page to read for the why.

Where this one is useful is the when: if the drop lines up with your dose increases and eases in the weeks between them, that pattern is at least consistent with the tolerability curve. If your desire is flat regardless of where you are in the dose schedule, the dose arc is probably not the explanation, and something else is worth looking at.

What to do with this

Track it against your dose dates, not your weight. A few weeks of notes will tell you whether your experience actually follows the escalation pattern or is independent of it. That distinction is genuinely useful to a prescriber, and nobody else can collect it for you.

Do not let escalation be treated as something to endure indefinitely. How side effects are managed, and when a slower climb is reasonable, is covered in managing GLP-1 side effects.

Rule out the ordinary explanations first. Exhaustion is the big one, and it has its own page in tiredness on a GLP-1. Fatigue suppresses desire in people who are not on any medication at all.

Do not assume maintenance is the finish line for this. What maintenance actually involves — and what happens if you come off — is in stopping a GLP-1, maintenance and rebound.

Where this sits on the evidence

Side effects cluster during dose escalation: strong. A phase 3 randomized trial of 751 adults published in the New England Journal of Medicine reports that adverse events were mostly mild to moderate and occurred primarily during dose escalation.

Tirzepatide produced more weight loss than semaglutide at 72 weeks: strong. 20.2% versus 13.7% in the same trial.

Sex drive recovers at maintenance: not studied. SURMOUNT-5 measured no sexual endpoints, and no trial has tracked sexual function across the escalation and maintenance phases. The expectation is reasonable and remains untested.

Your own pattern: worth collecting. Whether your desire tracks your dose schedule is something only you can observe, and it is the most informative thing you can bring to an appointment.